Akeso granted FDA fast track designation for bispecific antibody
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Akeso for Ak104, a bispecific antibody, as a monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer. Read More
Prometheus to develop antibody for IBD
Prometheus Biosciences has entered into an agreement with Dr. Falk Pharma for the development and commercialization of Pr600, a novel precision antibody, for the treatment of inflammatory bowel disease (IBD). Read More
NIH funds Celdara for pandemic influenza antiviral development
The U.S. National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases has awarded Celdara Medical a Small Business Innovation Research grant for the development of antivirals against pandemic and interpandemic influenzas. Read More
Vaccibody, Nektar begin customized cancer vaccine trial
Vaccibody and Nektar Therapeutics have started a phase I/IIA trial for a personalized cancer DNA vaccine for patients with advanced squamous cell carcinoma of the head and neck. Read More
ImmunoScape raises $11M to develop COVID-19 therapies
ImmunoScape has raised $11 million in financing to research how T-cell immune response contributes to COVID-19 immunity, with the goal of aiding in vaccine and therapy development. Read More
U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine. Read More
Will COVID-19 delay childhood vaccinations?
A recent survey from Orlando Health revealed that COVID-19 may be preventing children from receiving their normal vaccinations at local pediatrician offices. Read More
AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility. Read More
Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor, angiotensin-converting enzyme 2. Read More
Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
